Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Bladder cancer is the 10th most common cancer type in the world. There were more than
573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but
also by a non-negligible probability of recurrence and risk progression to muscle-invasive …

Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant
metastatic disease. Over the past three decades, perioperative cisplatin-based …

Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity
and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first …

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide
recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with …

Urothelial carcinoma is a common malignancy that carries a poor prognosis when the
disease includes muscle invasion. Metastatic urothelial carcinoma is almost uniformly fatal …

PURPOSE To evaluate the safety and efficacy of gemcitabine and cisplatin in combination
with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical …